Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
The Journal of Headache and Pain
Published in: The Journal of Headache and Pain 1/2018

Open Access 01-12-2018 | Review article

Transport of the pituitary adenylate cyclase-activating polypeptide across the blood-brain barrier: implications for migraine

Authors: Faisal Mohammad Amin, Henrik Winther Schytz

Published in: The Journal of Headache and Pain | Issue 1/2018

Login to get access

Abstract

Background

Pituitary adenylate cyclase-activating polypeptide (PACAP) is widely distributed in the nervous system and is involved in migraine pathophysiology. Understanding the function of the blood-brain barrier (BBB) in relation to PACAP is important to the understand the mechanisms behind PACAP-induced migraine attacks, but also to develop antimigraine drugs targeting the PACAP receptors Here, we aim to review the transport ability of PACAP across the BBB.

Methods

We performed a systematic literature search on PubMed to identify studies reporting original data on PACAP and BBB. The search was finalized in July 2017.

Results

The literature search identified 96 papers of which 11 contained relevant data. In addition, two papers were known to be relevant and were included. A total of 13 papers studies were included in the final analysis. Preclinical studies (n = 10) suggest the existence of specific PACAP transport systems across the BBB, while human PACAP studies failed to show vasodilator effect of PACAP on the cerebral arteries from the lumen (n = 3).

Conclusion

PACAP38 is transported over the BBB actively, while PACAP27 cross the BBB by diffusion over the membrane, but after crossing the endothelial membrane both isoforms are either rapidly degraded or efflux back from brain to blood. Thus, a direct central action of the PACAPs is unlikely. This is supported by studies showing selective PACAP effect on extra-cerebral arteries.
Literature
1.
Harmar AJ, Fahrenkrug J, Gozes I, Laburthe M, May V, Pisegna JR, Vaudry D, Vaudry H, Waschek JA, Said SI (2012) Pharmacology and functions of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide: IUPHAR review 1. Br J Pharmacol 166:4–17CrossRefPubMedPubMedCentral
2.
Schytz HW, Birk S, Wienecke T, Kruuse C, Olesen J, Ashina M (2009) PACAP38 induces migraine-like attacks in patients with migraine without aura. Brain 132:16–25CrossRefPubMed
3.
Guo S, Vollesen AL, Hansen RD, Esserlind AL, Amin FM, Christensen AF, Olesen J, Ashina M (2017) Part I: pituitary adenylate cyclase-activating polypeptide-38 induced migraine-like attacks in patients with and without familial aggregation of migraine. Cephalalgia 37:125–135CrossRefPubMed
4.
Amin FM, Asghar MS, Guo S, Hougaard A, Hansen AE, Schytz HW, van der Geest RJ, de Koning PJH, Larsson HBW, Olesen J, Ashina M (2012) Headache and prolonged dilatation of the middle meningeal artery by PACAP38 in healthy volunteers. Cephalalgia 32:140–149CrossRefPubMed
5.
Amin FM, Hougaard A, Schytz HW, Asghar MS, Lundholm E, Parvaiz AI, de Koning PJ, Andersen MR, Larsson HB, Fahrenkrug J, Olesen J, Ashina M (2014) Investigation of the pathophysiological mechanisms of migraine attacks induced by pituitary adenylate cyclase-activating polypeptide-38. Brain 137:779–794CrossRefPubMed
6.
Vaudry D, Falluel-Morel A, Bourgault S, Basille M, Burel D, Wurtz O, Fournier A, Chow BK, Hashimoto H, Galas L, Vaudry H (2009) Pituitary adenylate cyclase-activating polypeptide and its receptors: 20 years after the discovery. Pharmacol Rev 61:283–357CrossRefPubMed
7.
Dogrukol-Ak D, Tore F, Tuncel N (2004) Passage of VIP/PACAP/secretin family across the blood-brain barrier: therapeutic effects. Curr Pharm Des 10:1325–1340CrossRefPubMed
8.
Grände G, Nilsson E, Edvinsson L (2013) Comparison of responses to vasoactive drugs in human and rat cerebral arteries using myograph and pressurized cerebral artery method. Cephalalgia 33:152–159CrossRefPubMed
9.
10.
Banks WA, Kastin AJ, Komaki G, Arimura A (1993) Passage of pituitary adenylate cyclase activating polypeptide1-27 and pituitary adenylate cyclase activating polypeptide1-38 across the blood-brain barrier. J Pharmacol Exp Ther 267:690–696
11.
Banks WA, Kastin AJ, Arimura A (1998) Effect of spinal cord injury on the permeability of the blood-brain and blood-spinal cord barriers to the neurotropin PACAP. Exp Neurol 151:116–123CrossRefPubMed
12.
Mizushima H, Banks WA, Dohi K, Shioda S, Matsumoto H, Matsumoto K (1999) The effect of cardiac arrest on the permeability of the mouse blodd-brain and blood-spinal cord barrier to pituitary adenylate cyclase activating polypeptide (PACAP). Peptides 20:1337–1340CrossRefPubMed
13.
Mizushima H, Banks W, Dohi K, Nakamura Y, Matsumoto K, Shioda S (2000) The effect of cardiac arrest on the permeability of the mouse blood-brain and blood-spinal cord barriers to PACAP. Ann N Y Acad Sci 921:289–292CrossRefPubMed
14.
Nonaka N, Banks WA, Mizushima H, Shioda S, Morley JE (2002) Regional differences in PACAP transport across the blood-brain barrier in mice: a possible influence of strain, amyloid beta protein, and age. Peptides 23:2197–2202CrossRefPubMed
15.
Nonaka N, Shioda S, Banks WA (2005) Effect of lipopolysaccharide on the transport of pituitary adenylate cyclase activating polypeptide across the blood-brain barrier. Exp Neurol 191:137–144CrossRefPubMed
16.
Dogrukol-Ak D, Kumar VB, Ryerse JS, Farr SA, Verma S, Nonaka N, Nakamachi T, Ohtaki H, Niehoff ML, Edwards JC, Shioda S, Morley JE, Banks WA (2009) Isolation of peptide transport system-6 from brain entothelial cells: therapeutic effects with antisense inhibition in Alzheimer and stroke models. J Cereb Blood Flow Metab 29:411–422CrossRefPubMed
17.
Nonaka N, Farr SA, Nakamachi T, Morley JE, Nakamura M, Shioda S, Banks WA (2012) Intranasal administration of PACAP: uptake by brain and regional brain targeting with cyclodextrins. Peptides 36:168–175CrossRefPubMedPubMedCentral
18.
Yu R, Zeng Z, Guo X, Zhang H, Liu X, Ding Y, Chen J (2012) The TAT peptide endows PACAP with an enhanced ability to traverse bio-barriers. Neurosci Lett 527:1–5CrossRefPubMed
19.
Somogyvári-Vigh A, Pan W, Reglödi D, Kastin AJ, Arimura A (2000) Effect of middle cerebral artery occlusion on the passage of pituitary adenylate cyclase activating polypeptide across the blood-brain barrier in the rat. Regul Pept 91:89–95CrossRefPubMed
20.
Knutsson M, Edvinsson L (2002) Distribution of mRNA for VIP and PACAP receptors in human cerebral arteries and cranial ganglia. Neuroreport 13:507–509CrossRefPubMed
21.
Chan KY, Baun M, de Vries R, van den Bogaerdt AJ, Dirven CM, Danser AH, Jansen-Olesen I, Olesen J, Villalón CM, MaassenVanDenBrink A, Gupta S (2011) Pharmacological characterization of VIP and PACAP receptors in the human meningeal and coronary artery. Cephalalgia 31:181–189CrossRefPubMed
22.
Guo S, Vollesen AL, Olesen J, Ashina M (2016) Premonitory and nonheadache symptoms induced by CGRP and PACAP38 in patients with migraine. Pain 17:2773–2781CrossRef
23.
Maniyar FH, Sprenger T, Monteith T, Schankin C, Goadsby PJ (2014) Brain activations in the premonitory phase of nitroglycerin-triggered migraine attacks. Brain 137:232–241CrossRefPubMed
24.
Amin FM, Hougaard A, Magon S, Asghar MS, Ahmad NN, Rostrup E, Sprenger T, Ashina M (2016) Change in brain network connectivity during PACAP38-induced migraine attacks: a resting-state functional MRI study. Neurology 86:180–187CrossRefPubMed
25.
Ashina M, Tvedskov JF, Lipka K, Bilello J, Penkowa M, Olesen J (2010) Matrix metalloproteinases during and outside of migraine attacks without aura. Cephalalgia 30:303–310CrossRefPubMed
26.
Hougaard A, Amin FM, Christensen CE, Younis S, Wolfram F, Cramer SP, Larsson HBW, Ashina M (2017) Increased brainstem perfusion, but no blood-brain barrier disruption, during attacks of migraine with aura. Brain 140:1633–1642CrossRefPubMed
27.
Amin FM, Hougaard A, Cramer SP, Christensen CE, Wolfram F, Larsson HBW, Ashina M (2017) Intact blood-brain barrier during spontaneous attacks of migraine without aura: a 3T DCE-MRI study. Eur J Neurol 24:1116–1124CrossRefPubMed
Metadata
Title
Transport of the pituitary adenylate cyclase-activating polypeptide across the blood-brain barrier: implications for migraine
Authors
Faisal Mohammad Amin
Henrik Winther Schytz
Publication date
01-12-2018
Publisher
Springer Milan
Published in
The Journal of Headache and Pain / Issue 1/2018
Print ISSN: 1129-2369
Electronic ISSN: 1129-2377
DOI
https://doi.org/10.1186/s10194-018-0861-3

Other articles of this Issue 1/2018

The Journal of Headache and Pain 1/2018 Go to the issue

Research article

A PRISMA-compliant systematic review of the endpoints employed to evaluate symptomatic treatments for primary headaches

Research article

Vascular wall imaging in reversible cerebral vasoconstriction syndrome – a 3-T contrast-enhanced MRI study

Review article

PACAP and migraine headache: immunomodulation of neural circuits in autonomic ganglia and brain parenchyma

Consensus article

Guideline on the use of onabotulinumtoxinA in chronic migraine: a consensus statement from the European Headache Federation

Consensus article

Effect of exogenous estrogens and progestogens on the course of migraine during reproductive age: a consensus statement by the European Headache Federation (EHF) and the European Society of Contraception and Reproductive Health (ESCRH)

Letter to the Editor

Answer to the comment on Castien et al. (2018) pressure pain thresholds over the cranio-cervical region in headache - a systematic review and meta-analysis